Faculty profile

James Koropatnick

ResearcherWestern University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Western University directory, so their courses may be missing. Find their university profile.

James Koropatnick

Researcher

Health Sciences

Western University

London, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
2 publications in the last five years, latest in 2024.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2017.
Supervised 2 trainees who won CIHR awards, most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Western University profile.

Crispr/Cas9 Technology Dna Mismatch Repair Immune Checkpoint Inhibitors Immunotherapy New Cancer Therapies Sirna And Shrna

Latest papers

CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.
Frontiers in immunology · 2024 · senior author
Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory.
Molecular therapy : the journal of the American Society of Gene Therapy · 2023
TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer.
International journal of molecular sciences · 2021

All 44 publications

Latest funding

Inducing Mismatch Repair Deficiency in Cancer Cells for Therapeutic Benefit
CIHR · 2017 · Nominated PI
$983,025
The role of IDO1 vs IDO2 on tumour immune evasion and immune therapy
CIHR · 2012 · Co-investigator
$313,349
Folate receptor-targeting liposomes for delivery of antisense molecules to cancer cells
CIHR · 2012 · Supervisor
$17,500

All 7 grants and awards

44 publications.

CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.

Alotaibi FM, Min WP, Koropatnick J

Frontiers in immunology2024Senior author

DOI: 10.3389/fimmu.2024.1256766 PMID: 38487537

Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory.

El-Hajjar M, Gerhardt L, Hong MMY, Krishnamoorthy M, Figueredo R, Zheng X, Koropatnick J, Maleki Vareki S

Molecular therapy : the journal of the American Society of Gene Therapy2023

DOI: 10.1016/j.ymthe.2022.08.025 PMID: 36068918

TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer.

Liu Q, Xiong J, Xu D, Hao N, Zhang Y, Sang Y, Wang Z, Zheng X, Min J, Diao H, Raphael J, Maleki Vareki S, Koropatnick J, Min W

International journal of molecular sciences2021

DOI: 10.3390/ijms23010250 PMID: 35008676

Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function.

Alotaibi F, Vincent M, Min WP, Koropatnick J

Frontiers in immunology2020Senior author

DOI: 10.3389/fimmu.2020.584937 PMID: 33584650

miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.

Zhang M, Shi Y, Zhang Y, Wang Y, Alotaibi F, Qiu L, Wang H, Peng S, Liu Y, Li Q, Gao D, Wang Z, Yuan K, Dou FF, Koropatnick J, Xiong J, Min W

Cancer immunology, immunotherapy : CII2020

DOI: 10.1007/s00262-020-02507-w PMID: 32076794

CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity.

Alotaibi F, Rytelewski M, Figueredo R, Zareardalan R, Zhang M, Ferguson PJ, Maleki Vareki S, Najajreh Y, El-Hajjar M, Zheng X, Min WP, Koropatnick J

European journal of immunology2020Senior author

DOI: 10.1002/eji.201948309 PMID: 31943150

DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data.

Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, Maleki Vareki S

Methods in enzymology2020

DOI: 10.1016/bs.mie.2019.05.040 PMID: 32178827

miR-149-3p reverses CD8+ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells.

Zhang M, Gao D, Shi Y, Wang Y, Joshi R, Yu Q, Liu D, Alotaibi F, Zhang Y, Wang H, Li Q, Zhang ZX, Koropatnick J, Min W

Open biology2019

DOI: 10.1098/rsob.190061 PMID: 31594465

TdIF1: a putative oncogene in NSCLC tumor progression.

Zhang Y, Wang Z, Huang Y, Ying M, Wang Y, Xiong J, Liu Q, Cao F, Joshi R, Liu Y, Xu D, Zhang M, Yuan K, Zhou N, Koropatnick J, Min W

Signal transduction and targeted therapy2018

DOI: 10.1038/s41392-018-0030-9 PMID: 30345081

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.

Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, Maleki Vareki S

Oncoimmunology2018

DOI: 10.1080/2162402x.2018.1498439 PMID: 30288365

Something wrong or missing on this profile? Suggest a correction

James Koropatnick

Research

Latest papers

Latest funding

CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.

Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory.

TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer.

Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function.

miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.

CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity.

DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data.

miR-149-3p reverses CD8+ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells.

TdIF1: a putative oncogene in NSCLC tumor progression.

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.

Inducing Mismatch Repair Deficiency in Cancer Cells for Therapeutic Benefit

The role of IDO1 vs IDO2 on tumour immune evasion and immune therapy

Folate receptor-targeting liposomes for delivery of antisense molecules to cancer cells

BRCA2 and Thymidylate Synthase (TS) in Anti-Cancer Therapy

Electrochemical method for monitoring kinase activity

CIHR Training Grant in Cancer Research and Technology Transfer (CaRTT)

Intellectual Property Management 2001-02 Competition

Frequent collaborators

Xiufen Zheng

Weiping Min

Eric Winquist

Keith Kwan

Bret Wehrli

Bertha Garcia

Karel Tyml

Chao Wang

Suzanne Trudel

Bradley Urquhart

Hong Ling

Trevor Shepherd

Zhu-Xu Zhang

Qingping Feng

Paula Foster

James Koropatnick

Research

Latest papers

Latest funding

CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.

Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory.

TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer.

Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function.

miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.

CD5 blockade enhances ex vivo CD8+ T&#xa0;cell activation and tumour cell cytotoxicity.

DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data.

miR-149-3p reverses CD8+ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells.

TdIF1: a putative oncogene in NSCLC tumor progression.

Treatment-na&#xef;ve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.

Inducing Mismatch Repair Deficiency in Cancer Cells for Therapeutic Benefit

The role of IDO1 vs IDO2 on tumour immune evasion and immune therapy

Folate receptor-targeting liposomes for delivery of antisense molecules to cancer cells

BRCA2 and Thymidylate Synthase (TS) in Anti-Cancer Therapy

Electrochemical method for monitoring kinase activity

CIHR Training Grant in Cancer Research and Technology Transfer (CaRTT)

Intellectual Property Management 2001-02 Competition

Frequent collaborators

Xiufen Zheng

Weiping Min

Eric Winquist

Keith Kwan

Bret Wehrli

Bertha Garcia

Karel Tyml

Chao Wang

Suzanne Trudel

Bradley Urquhart

Hong Ling

Trevor Shepherd

Zhu-Xu Zhang

Qingping Feng

Paula Foster

CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity.

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.